AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20175039 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint training program (6 months)
Number of subjects: 12
Study 20175039 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 12
Study 18239639 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase healthy foods
Number of subjects: 41
Study 18239639 — intervention group
Group type: COMPARATOR
Intervention: Reduce high energy-dense foods
Number of subjects: 41
Study 16627574 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg transdermal nicotine patch (NIC)
Number of subjects: 12
Study 16627574 — intervention group
Group type: COMPARATOR
Intervention: colour‐matched placebo (PLA)
Number of subjects: 12
Study 12603713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal budesonide (64 microg per nasal cavity b.i.d)
Number of subjects: 0
Study 12603713 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 11045912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (Viagra) 10-100 mg, taken as needed approximately 1 hour prior to sexual activity
Number of subjects: 233
Study 11045912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 9193208 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine hydrochloride (8 or 16 mg)
Number of subjects: 142
Study 9193208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 1553900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus epirubicin (60 mg/m2 cisplatin + 75 mg/m2 epirubicin)
Number of subjects: 116
Study 1553900 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus doxorubicin (60 mg/m2 cisplatin + 60 mg/m2 doxorubicin)
Number of subjects: 116
Study 1553900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus epirubicin
Number of subjects: 116
Study 1553900 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus doxorubicin
Number of subjects: 116
Study 3546154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg
Number of subjects: 234
Study 3546154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg
Number of subjects: 234
Study 29709061 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 103
Study 28280319 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC/VI 62.5/25 µg
Number of subjects: 494
Study 28280319 — intervention group
Group type: COMPARATOR
Intervention: TIO 18 µg
Number of subjects: 494
Study 26502846 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional CT reconstruction and cephalometry
Number of subjects: 58
Study 26502846 — intervention group
Group type: COMPARATOR
Intervention: Conventional diagnostic technique
Number of subjects: 58
Study 23328113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-n-6 PUFA (L6) intervention
Number of subjects: 67
Study 23328113 — intervention group
Group type: EXPERIMENTAL
Intervention: High-n-3 PUFA, low-n-6 PUFA (H3-L6) intervention
Number of subjects: 67
Study 20872225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pueraria mirifica 25 mg
Number of subjects: 52
Study 20872225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pueraria mirifica 50 mg
Number of subjects: 52
Study 19449756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (physician/pharmacist collaboration)
Number of subjects: 0
Study 19449756 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 0
Study 17448262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine levonorgestrel
Number of subjects: 0
Study 17448262 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral progestogens
Number of subjects: 0
Study 17448262 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill
Number of subjects: 0
Study 17448262 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study 17448262 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 0
Study 17448262 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 0
Study 17448262 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophin-releasing hormone (GnRH) analogues
Number of subjects: 0
Study 14737756 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0
Study 14737756 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 12357478 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 80/4.5 microg, two inhalations twice daily (n = 148)
Number of subjects: 286
Study 12357478 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 100 microg, two inhalations twice daily (n = 138)
Number of subjects: 286
Study 9681285 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH dietary patterns
Number of subjects: 459
Study 9681285 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies (targeted mailings, mass mailings, community screenings, mass media advertising)
Number of subjects: 459
Study 9681285 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives ($150 to $160 reimbursement)
Number of subjects: 459
Study 9681285 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation willingness
Number of subjects: 459
Study 8006886 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 60
Study 8006886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3135194 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 0.1 mg.kg‐1
Number of subjects: 6
Study 3135194 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 0.2 mg.kg‐1
Number of subjects: 6
Study 3135194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30721737 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 66
Study 30721737 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 66
Study 28648402 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided graded exercise self-help (GES)
Number of subjects: 211
Study 28648402 — intervention group
Group type: COMPARATOR
Intervention: Specialist medical care (SMC) alone (control group)
Number of subjects: 211
Study 26457155 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal ultrasound curriculum
Number of subjects: 48
Study 26457155 — intervention group
Group type: COMPARATOR
Intervention: No longitudinal ultrasound curriculum (Control)
Number of subjects: 48
Study 23731525 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene intervention consisting of HH products, training, team training sessions, and reminders.
Number of subjects: 600
Study 23731525 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group) in 35 DCCs.
Number of subjects: 600
Study 23731525 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene intervention.
Number of subjects: 600
Study 20817685 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist-delivered adherence support service
Number of subjects: 142
Study 20817685 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 142
Study 19167078 — intervention group
Group type: EXPERIMENTAL
Intervention: Center point thickness measured by OCT in CRVO participants
Number of subjects: 665
Study 19167078 — intervention group
Group type: EXPERIMENTAL
Intervention: Center point thickness measured by OCT in BRVO participants
Number of subjects: 665
Study 17121065 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier-enhancing cosmetic moisturizer with vitamins (niacinamide, panthenol, tocopheryl acetate)
Number of subjects: 0
Study 17121065 — intervention group
Group type: COMPARATOR
Intervention: Cosmetic moisturizer without vitamins
Number of subjects: 0
Study 15621107 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrocautery for division of left renal vein branches
Number of subjects: 160
Study 15621107 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrocautery
Number of subjects: 160
Study 11762152 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormone replacement therapy (n = 19)
Number of subjects: 37
Study 11762152 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (n = 18)
Number of subjects: 37
Study 11762152 — intervention group
Group type: COMPARATOR
Intervention: Comparison of oral vs transdermal hormone replacement therapy
Number of subjects: 37
Study 9407675 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg (2 x ED90)
Number of subjects: 60
Study 9407675 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg/kg (2 x ED90)
Number of subjects: 60
Study 8498661 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sufentanil (SIV)
Number of subjects: 45
Study 8498661 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (SEPI)
Number of subjects: 45
Study 8498661 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl (FEPI)
Number of subjects: 45
Study 3367257 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg melatonin
Number of subjects: 0
Study 3367257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29880048 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led physical activity intervention (PLAN-A)
Number of subjects: 427
Study 29880048 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 427
Study 29238675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygopalatine fossa infiltration with 2% lignocaine and 1:80,000 adrenaline
Number of subjects: 68
Study 29238675 — intervention group
Group type: COMPARATOR
Intervention: Control side (non-infiltrated)
Number of subjects: 68
Study 25684570 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 344
Study 25684570 — intervention group
Group type: COMPARATOR
Intervention: UFH+VKA
Number of subjects: 344
Study 23433534 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended culture for 16-18h (EC group, n=242)
Number of subjects: 479
Study 23433534 — intervention group
Group type: COMPARATOR
Intervention: Conventional culture for 2h (control group, n=237)
Number of subjects: 479
Study 20653677 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (5 mg kg(‐1))
Number of subjects: 13
Study 20653677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 18662152 — intervention group
Group type: EXPERIMENTAL
Intervention: OL-S-HDF
Number of subjects: 16
Study 18662152 — intervention group
Group type: COMPARATOR
Intervention: OL-P-HDF
Number of subjects: 16
Study 18662152 — intervention group
Group type: COMPARATOR
Intervention: HF-HD
Number of subjects: 16
Study 16960164 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with n-6:n-3 ratio of approximately 3:1 enriched with EPA and DHA
Number of subjects: 258
Study 16960164 — intervention group
Group type: COMPARATOR
Intervention: Control diet with n-6:n-3 ratio of 10:1
Number of subjects: 258
Study 16960164 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal containing 50 g fat
Number of subjects: 258
Study 16960164 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding foods high in fat the day before measurement
Number of subjects: 258
Study 15275751 — intervention group
Group type: EXPERIMENTAL
Intervention: ATC dosing of acetaminophen with codeine (120 mg/12 mg/5 ml) every 4 h for 3 days
Number of subjects: 80
Study 15275751 — intervention group
Group type: COMPARATOR
Intervention: PRN dosing of acetaminophen with codeine (120 mg/12 mg/5 ml) every 4 h PRN for 3 days
Number of subjects: 80
Study 15275751 — intervention group
Group type: EXPERIMENTAL
Intervention: ATC dosing of acetaminophen with codeine with nurse coaching (120 mg/12 mg/5 ml) every 4 h for 3 days
Number of subjects: 80
Study 11404441 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cycle per degree (cpd) gratings, counterphase-reversed in contrast at either 3.3 or 5.5 Hz with a mask of either the same or orthogonal orientation
Number of subjects: 0
Study 11404441 — intervention group
Group type: COMPARATOR
Intervention: Adults
Number of subjects: 0
Study 9405024 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH)
Number of subjects: 32
Study 9405024 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 8495774 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of intranasal nafarelin
Number of subjects: 0
Study 8495774 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of intranasal nafarelin
Number of subjects: 0
Study 8495774 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3450521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 75
Study 3450521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 30873633 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxeed Plus for 6 months
Number of subjects: 175
Study 30873633 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxeed Plus
Number of subjects: 175
Study 28240758 — intervention group
Group type: EXPERIMENTAL
Intervention: MIMERACI technique
Number of subjects: 100
Study 28240758 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique (group A)
Number of subjects: 100
Study 26665290 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen One: Arm & Hammer Truly Radiant toothpaste and Arm & Hammer Truly Radiant Extra Whitening Spinbrush
Number of subjects: 60
Study 26665290 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen Two: Arm & Hammer Truly Radiant toothpaste, Arm & Hammer Truly Radiant Extra Whitening Spinbrush, and a whitening booster
Number of subjects: 60
Study 26665290 — intervention group
Group type: COMPARATOR
Intervention: Regimen Three: Colgate Cavity Protection toothpaste and an ADA standard manual brush
Number of subjects: 60
Study 24055212 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine 2 mg/24 h
Number of subjects: 284
Study 24055212 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine 3 mg/24 h
Number of subjects: 284
Study 24055212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 21145183 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-attentional bias (alcohol Stroop task)
Number of subjects: 0
Study 21145183 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsive decision-making (delay discounting task)
Number of subjects: 0
Study 21145183 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired inhibitory control (GO-NOGO task)
Number of subjects: 0
Study 21145183 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-attentional bias and impulsive decision-making
Number of subjects: 0
Study 21145183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive measures (alcohol-attentional bias, impulsive decision-making, impaired inhibitory control)
Number of subjects: 0
Study 21145183 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsive decision-making and impaired inhibitory control
Number of subjects: 0
Study 19719796 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivationally Enhanced (ME) treatment plus Nicotine Replacement Therapy (NRT)
Number of subjects: 444
Study 19719796 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC) treatment plus Nicotine Replacement Therapy (NRT)
Number of subjects: 444
Study 19719796 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT contact
Number of subjects: 444
Study 17720019 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine plus dobutamine
Number of subjects: 330
Study 17720019 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 330
Study 15120803 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior angina (n = 111)
Number of subjects: 283
Study 15120803 — intervention group
Group type: COMPARATOR
Intervention: No prior angina (n = 172)
Number of subjects: 283
Study 15120803 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with prior angina
Number of subjects: 283
Study 11676096 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthesized voice (extrovert or introvert)
Number of subjects: 0
Study 11676096 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthesized voice with added personality of the text
Number of subjects: 0
Study 9389778 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oestradiol (1.0 g Divigel/Sandrena 0.1% gel) applied on a 200 cm2 area
Number of subjects: 16
Study 9389778 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oestradiol (1.0 g Divigel/Sandrena 0.1% gel) applied on a 400 cm2 area
Number of subjects: 16
Study 9389778 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oestradiol (1.0 g Divigel/Sandrena 0.1% gel) applied on the largest possible area
Number of subjects: 16
Study 9389778 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing of the application site 30 min after application
Number of subjects: 16
Study 9389778 — intervention group
Group type: EXPERIMENTAL
Intervention: All three application areas
Number of subjects: 16
Study 7958491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypoglycemia (6.4, 3.6, and 2.6 mmol/l)
Number of subjects: 26
Study 7958491 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoglycemia (6.4, 3.6, and 2.6 mmol/l)
Number of subjects: 26
Study 7958491 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia (control day)
Number of subjects: 26
Study 7958491 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat testing after 3 months (experimental day protocol)
Number of subjects: 26
Study 7958491 — intervention group
Group type: EXPERIMENTAL
Intervention: History of unconsciousness due to hypoglycemia
Number of subjects: 26
Study 7958491 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (Men vs Women)
Number of subjects: 26
Study 2891531 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐methyl‐noradrenaline
Number of subjects: 6
Study 2891531 — intervention group
Group type: EXPERIMENTAL
Intervention: methoxamine
Number of subjects: 6
Study 2891531 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg)
Number of subjects: 6
Study 31015068 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 20
Study 31015068 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (AVP)
Number of subjects: 20
Study 31015068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29023319 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 90
Study 29023319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 90
Study 29023319 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 90
Study 26560512 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 142
Study 26560512 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 142
Study 23941610 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual advisor walking intervention
Number of subjects: 40
Study 23941610 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 40
Study 22068326 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist interventions on antibiotic use
Number of subjects: 0
Study 22068326 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacist interventions)
Number of subjects: 0
Study 19783714 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 60 mg (days 1‐7)
Number of subjects: 50
Study 19783714 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg (days 8‐14)
Number of subjects: 50
Study 19783714 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 90 mg (days 1‐7)
Number of subjects: 50
Study 17108342 — intervention group
Group type: EXPERIMENTAL
Intervention: Target hemoglobin value in the normal range (13.0 to 15.0 g per deciliter, group 1)
Number of subjects: 603
Study 17108342 — intervention group
Group type: COMPARATOR
Intervention: Subnormal hemoglobin range (10.5 to 11.5 g per deciliter, group 2)
Number of subjects: 603
Study 17108342 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (normal range)
Number of subjects: 603
Study 17108342 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (subnormal range)
Number of subjects: 603
Study 12957732 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ASD
Number of subjects: 62
Study 12957732 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 62
Study 11103749 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial grapefruit juice
Number of subjects: 4
Study 11103749 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit segments
Number of subjects: 4
Study 11103749 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit extract
Number of subjects: 4
Study 11103749 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 4
Study 8813223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet
Number of subjects: 30
Study 8813223 — intervention group
Group type: EXPERIMENTAL
Intervention: Atamet
Number of subjects: 30
Study 1533090 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg oral micronized dehydroepiandrosterone
Number of subjects: 8
Study 1533090 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg oral micronized dehydroepiandrosterone
Number of subjects: 8
Study 1533090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3925707 — intervention group
Group type: EXPERIMENTAL
Intervention: Aureomycin mouth rinse
Number of subjects: 0
Study 3925707 — intervention group
Group type: COMPARATOR
Intervention: Zendium dentifrice
Number of subjects: 0
Study 3925707 — intervention group
Group type: COMPARATOR
Intervention: Zendium dentifrice (pH changed from 5.9 to 6.8)
Number of subjects: 0
Study 31176622 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate + prednisone (AAP) + luteinising hormone-releasing hormone agonist (LHRHa)
Number of subjects: 65
Study 31176622 — intervention group
Group type: COMPARATOR
Intervention: Luteinising hormone-releasing hormone agonist (LHRHa) alone
Number of subjects: 65
Study 30185192 — intervention group
Group type: EXPERIMENTAL
Intervention: Replicating Effective Programs (REP)
Number of subjects: 200
Study 30185192 — intervention group
Group type: EXPERIMENTAL
Intervention: REP + coaching
Number of subjects: 200